

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited (“Stock Exchange”) take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



**RENAISSANCE ASIA SILK ROAD GROUP LIMITED**

**復興亞洲絲路集團有限公司**

*(incorporated in the Cayman Islands with limited liability)*

**(Stock code: 274)**

- (1) CHANGE OF CHIEF FINANCIAL OFFICER**  
**(2) REDESIGNATION OF NON-EXECUTIVE DIRECTOR AND VICE CHAIRMAN OF THE BOARD**  
**(3) UPDATE ON DIRECTOR’S INFORMATION PURSUANT TO RULE 13.51(2)(I) AND RULE 13.51B(2) OF THE LISTING RULES**  
**AND**  
**(4) CHANGE OF ADDRESS OF HONG KONG BRANCH SHARE REGISTRAR AND TRANSFER OFFICE**

**CHANGE OF CHIEF FINANCIAL OFFICER AND REDESIGNATION OF NON-EXECUTIVE DIRECTOR AND VICE CHAIRMAN OF THE BOARD**

The board (“**Board**”) of directors (“**Directors**” and each a “**Director**”) of Renaissance Asia Silk Road Group Limited (“**Company**”, together with its subsidiaries collectively referred to as “**Group**”) announces that due to change in work arrangements, Dr. Wang Wei Hsin (“**Dr. Wang**”) has been redesignated from the chief financial officer of the Company (“**CFO**”) to a non-executive director of the Company (“**NED**”) and the vice chairman of the Board (“**Vice Chairman**”) with effect from the conclusion of the Board meeting held on 20 July 2022.

The Board is pleased to announce that Ms. Jiang Ying (“**Ms. Jiang**”) has been redesignated from the financial manager of the Company to CFO with effect from the conclusion of the Board meeting held on 20 July 2022.

The biographical details of Dr. Wang and Ms. Jiang are as follows:

**Dr. Wang Wei Hsin**, aged 56, has extensive management experience in the financial services industry. Dr. Wang is an independent non-executive director of Huscoke Holdings Limited since December 2018 ((formerly known as Huscoke Resources Holdings Limited, a company listed on the Stock Exchange (stock code: 704)), and he served as an executive director of South China Financial Holdings Limited (a company listed on the Stock Exchange (stock code: 619)) from 2017 to 2018, the chairman and chief executive officer of SinoPac Securities (Asia) Limited from 2009 to 2016, the chief investment officer of Japan CDW Group and the chief financial officer of its Taiwan subsidiary, as well as co-founder of Yes-Asia.com and played significant role in China Development Industrial Bank. Dr. Wang obtained a PhD in Management Science (Financial Engineering) from Imperial College London in 1999.

Dr. Wang has entered into an appointment letter with the Company in respect of his appointment as a NED for a term of one year starting from 20 July 2022. Dr. Wang is subject to retirement and re-election at the next following general meeting of the Company after his appointment and thereafter subject to retirement by rotation in accordance with the provisions of the Company's articles of association. Dr. Wang is entitled to a director fee of HK\$30,000 per month which has been fixed by the Board with reference to, including but not limited to, his duties, responsibilities, performance, prevailing market conditions and remuneration benchmark relevant to other directors of listed companies of similar size and industry nature.

Save as disclosed above, Dr. Wang has confirmed that as at the date of this announcement, he (i) does not hold any directorship in other public companies the securities of which are listed on any securities market in Hong Kong or overseas in the last three years; (ii) does not hold any other position with the Company and other members of the Group or other major appointments and professional qualifications; (iii) does not have any relationship with other Directors, senior management, substantial or controlling shareholders of the Company; and (iv) does not have interests in the shares of the Company which are required to be disclosed pursuant to Part XV of the Securities and Futures Ordinance.

Save as disclosed above, there are no other matters in relation to the redesignation of Dr. Wang from CFO to NED and Vice Chairman that need to be brought to the attention of the shareholders of the Company ("**Shareholders**") and there is no other information that should be disclosed pursuant to rules 13.51(2)(h) to (v) of the Rules Governing the Listing of Securities on the Stock Exchange ("**Listing Rules**").

**Ms. Jiang Ying**, aged 36, joined the Group in June 2021 as the financial manager of the Group, mainly responsible for financial management. Before joining the Group, she had served as chief financial officer and other financial positions in various enterprises in Hong Kong and China. Ms. Jiang obtained a bachelor's degree in accounting from Hunan Agricultural University, China in 2007.

The Board would like to take this opportunity to welcome Dr. Wang and Ms. Jiang to her new role in the Group.

### **List of Directors and Their Roles and Functions**

With effect from 20 July 2022, immediately after the closure of the Board meeting, the members of the Board are set out below:

| <u>Executive Directors:</u>                           | <u>Non-executive Director:</u> | <u>Independent non-executive Directors:</u> |
|---|--------------------------------|---|
| Mr. Qiu Zhenyi ( <i>Chairman of the Board</i> )       | Dr. Wang Wei Hsin              | Mr. Au-Yong Shong Samuel                    |
| Mr. Zhu Shengsheng ( <i>Chief executive officer</i> ) | Ms. Ng Ching                   | Mr. Chen Jian                               |
| Mr. Pan Feng  |                                | Mr. Tse Sze Pan                             |
| Mr. Xie Qiangming                                     |                                |   |

The table below provides the latest membership information of the Company’s audit committee, remuneration committee and nomination committee on which each Board member serves:

| Board Committees<br>Directors | Audit<br>Committee | Remuneration<br>Committee | Nomination<br>Committee |
|-------------------------------|--------------------|---------------------------|-------------------------|
| Mr. Qiu Zhenyi                |                    |                           | C                       |
| Mr. Pan Feng                  |                    |                           |                         |
| Mr. Xie Qiangming             |                    | M                         | M                       |
| Mr. Zhu Shengsheng            |                    |                           |                         |
| Dr. Wang Wei Hsin             |                    |                           |                         |
| Ms. Ng Ching                  |                    |                           |                         |
| Mr. Au-Yong Shong Samuel      | C                  | M                         | M                       |
| Mr. Chen Jian                 | M                  | M                         | M                       |
| Mr. Tse Sze Pan               | M                  | C                         | M                       |

Notes:

C: Chairman of the relevant Board committees

M: Member of the relevant Board committees

#### **UPDATE ON DIRECTOR’S INFORMATION PURSUANT TO RULE 13.51(2)(I) AND RULE 13.51B(2) OF THE LISTING RULES**

Pursuant to the disclosure requirement under rules 13.51B(2) and 13.51(2)(I) of the Listing Rules, the Company would like to inform the public of the following updates on particulars of Mr. Xie Qiangming (“**Mr. Xie**”), an executive Director:

The Company has been notified by Mr. Xie that he was appointed as an executive director of Prosperity International Holdings (H.K.) Limited (“**Prosperity**”) in July 2019, and was subsequently further appointed as chief executive officer and chairman of the board until his resignation in June 2021. On 29 November 2019, Prosperity filed a winding up petition with the Supreme Court of Bermuda (“**Bermuda Court**”) and subsequently appointed joint and several provisional liquidators to enable Prosperity to continue its orderly financial restructuring with the assistance of the Bermuda Court. On that date, creditors of Prosperity demanded repayment of debts totaling approximately HK\$1,472 million. According to the latest update announcement of Prosperity dated 4 March 2021, the Bermuda Court ordered, among others, that (1) the winding up petition be re-listed for mention on 12 March 2021; and (2) the fees and expenses of the joint and several provisional liquidators for the period 29 November 2019 to 31 December 2020 be approved in the sum of USD1,020,537. Reference is made to the announcements of Prosperity dated 29 November 2019, 23 January 2020, 27 April 2020, 15 June 2020, 18 February 2021, 24 February 2021 and 4 March 2021 (“**Announcements**”).

Based on public information available to the Company, Prosperity is a Bermuda incorporated investment holding company listed on the main board of the Stock Exchange (stock code: 803) principally engaged in (i) real estate investment and development; (ii) mining and trading of iron ore and raw materials; and (iii) trading of clinker, cement and other building materials. The securities of Prosperity have been suspended as at the date of this announcement.

The Board has no further information relating to the abovementioned winding up petition other than the information set out above which is based on the Announcements. Mr. Xie confirmed that he is not aware of any actual or potential claim that has been or will be made against him because of the above. He also confirmed that he has no knowledge at the present time of the possible outcome of the winding up petition.

Save as disclosed above, Mr. Xie has confirmed to the Company that there are no other matters relating to him that need to be brought to the attention of the Shareholders and there is no other information that should be disclosed pursuant to rules 13.51(2)(h) to (v) of the Listing Rules.

Save as disclosed above, all other particulars of Mr. Xie remain unchanged.

## **CHANGE OF ADDRESS OF HONG KONG BRANCH SHARE REGISTRAR AND TRANSFER OFFICE**

With effect from 15 August 2022, the Hong Kong Branch Share Registrar and Transfer Office of the Company, Tricor Tengis Limited (“**Branch Share Registrar**”), will change its address from Level 54, Hopewell Centre, 183 Queen’s Road East, Hong Kong to:

**17/F, Far East Finance Centre, 16 Harcourt Road, Hong Kong**

All telephone and facsimile numbers of the Branch Share Registrar will remain unchanged.

By order of the Board of  
**Renaissance Asia Silk Road Group Limited**  
**Qiu Zhenyi**  
*Chairman of the Board*

Hong Kong, 20 July 2022

As at the date of this announcement, immediately after the closure of the Board meeting, the Board comprises:

Executive Directors:

Mr. Qiu Zhenyi (*Chairman of the Board*)

Mr. Zhu Shengsheng (*Chief executive officer*)

Mr. Pan Feng

Mr. Xie Qiangming

Non-executive Director:

Dr. Wang Wei Hsin

Ms. Ng Ching

Independent non-executive Directors:

Mr. Au-Yong Shong Samuel

Mr. Chen Jian

Mr. Tse Sze Pan